Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Patient and physician preferences for attributes of biologic medications for severe asthma.

Gelhorn HL, Balantac Z, Ambrose CS, Chung YN, Stone B.

Patient Prefer Adherence. 2019 Jul 25;13:1253-1268. doi: 10.2147/PPA.S198953. eCollection 2019.

2.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.

Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.

PMID:
31229240
3.

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.

Gelhorn HL, Gries KS, Speck RM, Duus EM, Bourne RK, Aggarwal D, Cella D.

Qual Life Res. 2019 Jun;28(6):1641-1653. doi: 10.1007/s11136-019-02135-7. Epub 2019 Feb 22.

PMID:
30796591
4.

The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS).

Gelhorn HL, Ye X, Speck RM, Tong S, Healey JH, Bukata SV, Lackman RD, Murray L, Maclaine G, Lenderking WR, Hsu HH, Lin PS, Tap WD.

J Patient Rep Outcomes. 2019 Feb 4;3(1):6. doi: 10.1186/s41687-019-0099-0.

5.

Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.

Gelhorn HL, Skalicky AM, Balantac Z, Eremenco S, Cimms T, Halling K, Hollen PJ, Gralla RJ, Mahoney MC, Sexton C.

Support Care Cancer. 2018 Jul;26(7):2229-2238. doi: 10.1007/s00520-018-4061-0. Epub 2018 Feb 1.

PMID:
29392480
6.

Qualitative interviews to identify burden of illness, impacts and costs associated with surgical site infections.

Gelhorn HL, Anand SB, Parvizi J, Morrison T, Yu H, Pokrzywinski R, Al-Jassar G, Chen AF.

J Comp Eff Res. 2018 Apr;7(4):357-367. doi: 10.2217/cer-2017-0075. Epub 2017 Nov 9.

7.

Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.

Jones PW, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158. doi: 10.15326/jcopdf.4.2.2017.0132.

8.

St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

Müllerova H, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Rennard SI, Tabberer M, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.

9.

Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.

Jones PW, Gelhorn H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.

10.

Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.

Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.

11.

The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.

Tabberer M, Benson VS, Gelhorn H, Wilson H, Karlsson N, Müllerova H, Menjoge S, Rennard SI, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.

12.

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q-SF).

Gelhorn HL, Roberts LJ, Khandelwal N, Revicki DA, DeRogatis LR, Dobs A, Hepp Z, Miller MG.

J Sex Med. 2017 Aug;14(8):1046-1058. doi: 10.1016/j.jsxm.2017.05.013.

PMID:
28760247
13.

MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment.

Tervonen T, Gelhorn H, Sri Bhashyam S, Poon JL, Gries KS, Rentz A, Marsh K.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1483-1491. doi: 10.1002/pds.4255. Epub 2017 Jul 11.

PMID:
28696023
14.

Content validity and ePRO usability of the BPI-sf and "worst pain" item with pleural and peritoneal mesothelioma.

Gelhorn HL, Eremenco S, Skalicky AM, Balantac Z, Cimms T, Halling K, Sexton C.

J Patient Rep Outcomes. 2017;2(1):16. doi: 10.1186/s41687-018-0039-4. Epub 2018 Mar 27.

15.

Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: Qualitative Research.

Gelhorn HL, Bodhani AR, Wahala LS, Sexton C, Landrian A, Miller MG, Derogatis L, Dobs A, Revicki DA.

J Sex Med. 2016 Nov;13(11):1729-1736. doi: 10.1016/j.jsxm.2016.09.007. Epub 2016 Oct 4.

16.

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire.

Gelhorn HL, Dashiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, Althof SE, Brod M, Revicki DA.

J Sex Med. 2016 Nov;13(11):1737-1749. doi: 10.1016/j.jsxm.2016.09.006. Epub 2016 Sep 28.

17.

Preference for pharmaceutical formulation and treatment process attributes.

Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, Gelhorn HL.

Patient Prefer Adherence. 2016 Jul 27;10:1385-99. doi: 10.2147/PPA.S101821. eCollection 2016. Review.

18.

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.

Gelhorn HL, Bacci ED, Poon JL, Boye KS, Suzuki S, Babineaux SM.

Patient Prefer Adherence. 2016 Jul 25;10:1337-48. doi: 10.2147/PPA.S109289. eCollection 2016.

19.

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, Lenderking W, Ye X, Speck RM, Lackman RD, Bukata SV, Healey JH, Keedy VL, Anthony SP, Wagner AJ, Von Hoff DD, Singh AS, Becerra CR, Hsu HH, Lin PS, Tap WD.

Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.

20.

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.

Gelhorn HL, Kulke MH, O'Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P, Lapuerta P.

Clin Ther. 2016 Apr;38(4):759-68. doi: 10.1016/j.clinthera.2016.03.002. Epub 2016 Mar 31.

21.

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.

Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS.

Patient Prefer Adherence. 2015 Nov 9;9:1611-22. doi: 10.2147/PPA.S90842. eCollection 2015.

22.

Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism.

Gelhorn HL, Vernon MK, Stewart KD, Miller MG, Brod M, Althof SE, DeRogatis LR, Dobs A, Seftel AD, Revicki DA.

Patient. 2016 Apr;9(2):181-90. doi: 10.1007/s40271-015-0138-8.

PMID:
26334870
23.

German Patients' Preferences for Attributes Of Type 2 Diabetes Medications.

Gelhorn H, Stringer S, Reinders S, Schreeb K.

Value Health. 2014 Nov;17(7):A354. doi: 10.1016/j.jval.2014.08.750. Epub 2014 Oct 26. No abstract available.

24.

Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data.

Chen WH, Lenderking W, Jin Y, Wyrwich KW, Gelhorn H, Revicki DA.

Qual Life Res. 2014 Mar;23(2):485-93. doi: 10.1007/s11136-013-0487-5. Epub 2013 Aug 3.

PMID:
23912855
25.

Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.

Gelhorn HL, Stringer SM, Brooks A, Thompson C, Monz BU, Boye KS, Hach T, Lund SS, Palencia R.

Diabetes Obes Metab. 2013 Sep;15(9):802-9. doi: 10.1111/dom.12091. Epub 2013 Apr 7.

PMID:
23464623
26.

Measurement invariance of the Beck Depression Inventory-Second Edition (BDI-II) across gender, race, and ethnicity in college students.

Whisman MA, Judd CM, Whiteford NT, Gelhorn HL.

Assessment. 2013 Aug;20(4):419-28. doi: 10.1177/1073191112460273. Epub 2012 Oct 7.

PMID:
23044895
27.

Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.

Gelhorn H, Merikle E, Krishnan S, Nemes L, Leissinger C, Valentino L.

Haemophilia. 2013 Jan;19(1):119-25. doi: 10.1111/hae.12011. Epub 2012 Sep 25.

PMID:
23005041
28.

Psychometric evaluation of health-related quality-of-life measures after pelvic organ prolapse surgery.

Gelhorn HL, Coyne KS, Sikirica V, Gauld J, Murphy M.

Female Pelvic Med Reconstr Surg. 2012 Jul-Aug;18(4):221-6. doi: 10.1097/SPV.0b013e31825e6707.

PMID:
22777371
29.

A behavioral test of accepting benefits that cost others: associations with conduct problems and callous-unemotionality.

Sakai JT, Dalwani MS, Gelhorn HL, Mikulich-Gilbertson SK, Crowley TJ.

PLoS One. 2012;7(4):e36158. doi: 10.1371/journal.pone.0036158. Epub 2012 Apr 27.

30.
31.

Patient preferences for treatment of major depressive disorder and the impact on health outcomes: a systematic review.

Gelhorn HL, Sexton CC, Classi PM.

Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01161. doi: 10.4088/PCC.11r01161.

32.

The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden.

Sexton CC, Gelhorn HL, Bell JA, Classi PM.

J Learn Disabil. 2012 Nov-Dec;45(6):538-64. doi: 10.1177/0022219411407772. Epub 2011 Jul 14. Review.

PMID:
21757683
33.

The psychometric validation of a 1-week recall period for the OAB-q.

Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z.

Int Urogynecol J. 2011 Dec;22(12):1555-63. doi: 10.1007/s00192-011-1486-0. Epub 2011 Jul 8.

PMID:
21739328
34.

Structure and etiology of co-occurring internalizing and externalizing disorders in adolescents.

Cosgrove VE, Rhee SH, Gelhorn HL, Boeldt D, Corley RC, Ehringer MA, Young SE, Hewitt JK.

J Abnorm Child Psychol. 2011 Jan;39(1):109-23. doi: 10.1007/s10802-010-9444-8.

35.

The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder.

Coyne KS, Cash B, Kopp Z, Gelhorn H, Milsom I, Berriman S, Vats V, Khullar V.

BJU Int. 2011 Jan;107(2):254-61. doi: 10.1111/j.1464-410X.2010.09446.x.

36.

Using trajectory analyses to refine phenotype for genetic association: conduct problems and the serotonin transporter (5HTTLPR).

Sakai JT, Boardman JD, Gelhorn HL, Smolen A, Corley RP, Huizinga D, Menard S, Hewitt JK, Stallings MC.

Psychiatr Genet. 2010 Oct;20(5):199-206. doi: 10.1097/YPG.0b013e32833a20f1.

37.

Test of association between GABRA2 (SNP rs279871) and adolescent conduct/alcohol use disorders utilizing a sample of clinic referred youth with serious substance and conduct problems, controls and available first degree relatives.

Sakai JT, Stallings MC, Crowley TJ, Gelhorn HL, McQueen MB, Ehringer MA.

Drug Alcohol Depend. 2010 Jan 15;106(2-3):199-203. doi: 10.1016/j.drugalcdep.2009.08.015. Epub 2009 Sep 23.

38.

An item response theory analysis of DSM-IV conduct disorder.

Gelhorn H, Hartman C, Sakai J, Mikulich-Gilbertson S, Stallings M, Young S, Rhee S, Corley R, Hewitt J, Hopfer C, Crowley T.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):42-50. doi: 10.1097/CHI.0b013e31818b1c4e.

39.

Toward DSM-V: an item response theory analysis of the diagnostic process for DSM-IV alcohol abuse and dependence in adolescents.

Gelhorn H, Hartman C, Sakai J, Stallings M, Young S, Rhee SH, Corley R, Hewitt J, Hopfer C, Crowley T.

J Am Acad Child Adolesc Psychiatry. 2008 Nov;47(11):1329-39. doi: 10.1097/CHI.0b013e318184ff2e.

40.

Case-control and within-family tests for an association between conduct disorder and DAT1.

Schulz-Heik RJ, Maentz SK, Rhee SH, Gelhorn HL, Young SE, Timberlake DS, Smolen A, Stetler GL, Sakai JT, Crowley TJ.

Psychiatr Genet. 2008 Feb;18(1):17-24. doi: 10.1097/YPG.0b013e3282ef48c8.

PMID:
18197081
41.

Item response theory analysis of DSM-IV cannabis abuse and dependence criteria in adolescents.

Hartman CA, Gelhorn H, Crowley TJ, Sakai JT, Stallings M, Young SE, Rhee SH, Corley R, Hewitt JK, Hopfer CJ.

J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):165-173. doi: 10.1097/chi.0b013e31815cd9f2.

42.

DSM-IV conduct disorder criteria as predictors of antisocial personality disorder.

Gelhorn HL, Sakai JT, Price RK, Crowley TJ.

Compr Psychiatry. 2007 Nov-Dec;48(6):529-38. Epub 2007 Aug 22.

43.

Common and specific genetic influences on aggressive and nonaggressive conduct disorder domains.

Gelhorn H, Stallings M, Young S, Corley R, Rhee SH, Christian H, Hewitt J.

J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):570-577. doi: 10.1097/01.chi.0000198596.76443.b0.

PMID:
16670651
44.

Genetic and environmental influences on conduct disorder: symptom, domain and full-scale analyses.

Gelhorn HL, Stallings MC, Young SE, Corley RP, Rhee SH, Hewitt JK.

J Child Psychol Psychiatry. 2005 Jun;46(6):580-91.

PMID:
15877764

Supplemental Content

Loading ...
Support Center